There are limited treatments for the number of diseases we see today, with a need to develop novel treatment options to address this. Nanomedicines refer to the application of nanoparticles for the prevention, diagnosis, and treatment of disease. It involves using different nanoparticles, including lipid-based nanoparticles, polymer-based nanoparticles, inorganic nanoparticles, drug nanocrystals, protein-based nanoparticles, conjugates, etc. The science of translation refers to the multistep process that generally involves turning research in labs, clinics, and communities into interventions or therapy that improve people’s lives through prevention, diagnostics, therapeutics, and medical procedures.
Nanomedicine research aims to revolutionize cancer prevention, diagnosis, and treatment. However, many great discoveries on anticancer nanomedicines that showed success in pre-clinical animal models, have failed to translate to clinical use in humans. For example, the concept of enhanced permeability and retention of nanoparticles works well in pre-clinical xenograft cancer models, however, translates poorly to humans due to the heterogeneity of cancers. Only a few nanomedicine-based therapies have reached the market due to several challenges that affect the translation of these therapies to treatment. These challenges include the lack of appropriate formulations and proper pre-clinical models. Furthermore, challenges in translating pre-clinical efficacy to clinical outcome, lack of funding resources, manufacturing and scale-up, pharmaceutical stability, obtaining clinical and regulatory approval, and the toxicity of the nanoparticles, etc. Elaborating and addressing the earlier mentioned issues will establish efficient translation from bench to bed to community.
This Research Topic aims to compile research involving nanoparticles used to prevent, diagnose, and treat cancer. This Topic welcomes all article types accepted to the section including, but not limited to, the following topics:
1. Basic research and application of nanomedicine for the treatment of cancer
2. Novel characterization tools, methods (in vitro and in vivo) and models for testing and predicting the performance and activity nanomedicines in cancer treatment
3. Toxicological data on nanomedicines and nanomaterials in cancer treatment
4. Assessment of molecular pathways associated with nanomedicines for cancer treatment
5. Industrial and regulatory guidelines and protocols for the development and characterization of nanomedicines
6. Negative or unexpected results concerning nanomedicine in anti-cancer treatment
7. Clinical applicability of novel nanomedicines for cancer treatment
8. Clinical research and guidelines on testing nanomedicines in cancer treatment.
There are limited treatments for the number of diseases we see today, with a need to develop novel treatment options to address this. Nanomedicines refer to the application of nanoparticles for the prevention, diagnosis, and treatment of disease. It involves using different nanoparticles, including lipid-based nanoparticles, polymer-based nanoparticles, inorganic nanoparticles, drug nanocrystals, protein-based nanoparticles, conjugates, etc. The science of translation refers to the multistep process that generally involves turning research in labs, clinics, and communities into interventions or therapy that improve people’s lives through prevention, diagnostics, therapeutics, and medical procedures.
Nanomedicine research aims to revolutionize cancer prevention, diagnosis, and treatment. However, many great discoveries on anticancer nanomedicines that showed success in pre-clinical animal models, have failed to translate to clinical use in humans. For example, the concept of enhanced permeability and retention of nanoparticles works well in pre-clinical xenograft cancer models, however, translates poorly to humans due to the heterogeneity of cancers. Only a few nanomedicine-based therapies have reached the market due to several challenges that affect the translation of these therapies to treatment. These challenges include the lack of appropriate formulations and proper pre-clinical models. Furthermore, challenges in translating pre-clinical efficacy to clinical outcome, lack of funding resources, manufacturing and scale-up, pharmaceutical stability, obtaining clinical and regulatory approval, and the toxicity of the nanoparticles, etc. Elaborating and addressing the earlier mentioned issues will establish efficient translation from bench to bed to community.
This Research Topic aims to compile research involving nanoparticles used to prevent, diagnose, and treat cancer. This Topic welcomes all article types accepted to the section including, but not limited to, the following topics:
1. Basic research and application of nanomedicine for the treatment of cancer
2. Novel characterization tools, methods (in vitro and in vivo) and models for testing and predicting the performance and activity nanomedicines in cancer treatment
3. Toxicological data on nanomedicines and nanomaterials in cancer treatment
4. Assessment of molecular pathways associated with nanomedicines for cancer treatment
5. Industrial and regulatory guidelines and protocols for the development and characterization of nanomedicines
6. Negative or unexpected results concerning nanomedicine in anti-cancer treatment
7. Clinical applicability of novel nanomedicines for cancer treatment
8. Clinical research and guidelines on testing nanomedicines in cancer treatment.
